Is Gene Biotherapeutics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Gene Biotherapeutics Inc (CRXM) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Gene Biotherapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Gene Biotherapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Gene Biotherapeutics Inc?

Muslim investors may consider investing in Gene Biotherapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Gene Biotherapeutics Inc classified as NOT COVERED?

Musaffa determines the Shariah status of Gene Biotherapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Gene Biotherapeutics Inc updated?

The Shariah compliance status of Gene Biotherapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Gene Biotherapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Gene Biotherapeutics Inc?

You can check the latest Shariah compliance status of Gene Biotherapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Gene Biotherapeutics Inc. Stock Analysis CRXM

United States Health Care Nano Cap

Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company. The company is headquartered in San Diego, California. The technology platform is designed to biologically activate the human body's innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral, and other medical conditions and diseases, as well as for advanced tissue engineering applications. Its lead product candidate Generx (Ad5FGF-4) is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. The Generx product candidate is under clinical development, which is cleared by the United States Food and Drug Administration (FDA) for a Phase III clinical study.

Financial Metrics & Statements of Gene Biotherapeutics Inc (CRXM)

FAQ's for Gene Biotherapeutics Inc (CRXM)

According to Musaffa’s Shariah screening methodology, Gene Biotherapeutics Inc (CRXM) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.